Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference

Core Viewpoint - Immunome, Inc. is focused on developing innovative targeted cancer therapies and will present at the 2nd Annual Guggenheim Healthcare Innovation Conference on November 11, 2025 [1][2]. Company Overview - Immunome is a clinical-stage biotechnology company dedicated to creating first-in-class and best-in-class targeted therapies for cancer patients [3]. - The company has a portfolio that includes advanced pipeline programs such as varegacestat, IM-1021, and IM-3050, with various stages of clinical trials [3]. Pipeline and Research - The most advanced programs include: - Varegacestat (formerly AL102), a gamma secretase inhibitor in Phase 3 trials for desmoid tumors [3]. - IM-1021, a ROR1-targeted ADC currently in Phase 1 trials [3]. - IM-3050, a FAP-targeted radioligand that has recently received IND clearance [3]. - Immunome has also presented preclinical data indicating that its proprietary ADC payload HC74 can overcome multiple mechanisms of ADC resistance [5]. Inducement Grants - On October 1, 2025, Immunome granted inducement awards consisting of non-statutory stock options for 69,000 shares to five new employees [6]. - Additionally, on September 2, 2025, the company granted inducement awards for 117,000 shares to eight new employees [7].